PlacidWay Expands Network for CAR-T and Gene-Based Therapies in China
PlacidWay Medical Tourism has expanded its network of medical providers in China offering CAR-T cell therapy and other cellular and gene-based treatments for eligible international patients.
DENVER, Colo., July 22, 2026 — PlacidWay Medical Tourism has expanded its network of medical providers in China offering cellular and gene-based therapies, including CAR-T cell therapy, tumor-infiltrating lymphocyte therapy, natural killer cell therapy, and gene therapy.
The expansion provides international patients with additional information about treatment options available through participating providers in China. Patients may use the PlacidWay platform to review provider profiles, learn about reported treatment approaches, and contact medical teams for case evaluation.
Cellular and Gene-Based Treatment Options
CAR-T cell therapy is a form of immunotherapy in which a patient’s T cells are collected, modified to recognize specific targets, and returned to the patient. Depending on the treatment program and physician assessment, the therapy may be considered for certain blood cancers and other conditions under clinical or regulated medical protocols.
Other treatment approaches available through providers in the network include tumor-infiltrating lymphocyte therapy, which uses immune cells collected from tumor tissue, and natural killer cell therapy, which uses immune cells involved in the body’s response to abnormal cells.
Gene therapy programs may involve introducing, removing, or modifying genetic material for a specific medical purpose.
Provider availability, treatment eligibility, clinical protocols, and regulatory requirements vary by institution and patient condition. Each case requires medical review, and not every patient will qualify for treatment.
Conditions Evaluated by Participating Providers
Providers within the expanded network report evaluating patients with conditions such as:
B-cell acute lymphoblastic leukemia
Multiple myeloma
Chronic lymphocytic leukemia
Non-Hodgkin lymphoma
Diffuse large B-cell lymphoma
Systemic lupus erythematosus
Myasthenia gravis
The inclusion of a condition does not mean that a particular treatment is appropriate or approved for every patient. Suitability depends on the diagnosis, disease stage, previous treatment history, laboratory findings, treatment protocol, and physician assessment.
“International patients need clear information about where specific cellular and gene-based therapies are available and how eligibility is determined,” said Pramod Goel, founder and CEO of PlacidWay Medical Tourism. “This expansion is intended to help patients review providers in China and communicate with medical teams before making decisions about care.”
Through its platform, PlacidWay provides access to provider profiles, treatment information, and direct inquiry channels. The company does not determine medical eligibility or select treatments for patients. Medical decisions are made between patients and licensed healthcare professionals following clinical review.
Patients considering treatment abroad should review the provider’s credentials, treatment protocol, potential benefits and risks, follow-up requirements, total costs, and applicable regulatory status. They should also consult their current physician before traveling or changing an existing treatment plan.
About PlacidWay Medical Tourism
Founded in 2007 and headquartered in Denver, Colorado, PlacidWay is a healthcare information and provider-discovery platform. It allows patients to review medical providers, treatment options, locations, and inquiry information for healthcare services offered in multiple countries.
About PlacidWay’s Cellular Therapy Network in China
PlacidWay’s cellular therapy network in China includes participating medical providers offering information about CAR-T cell therapy, tumor-infiltrating lymphocyte therapy, natural killer cell therapy, and gene therapy. Treatment availability and patient eligibility vary by provider and require direct medical evaluation.
More information is available at:
https://www.placidway.com/search-medical-centers/CAR-T-Therapy-for-Gastric-Cancer+CAR-T-Cell-Therapy/China/1
Media Contact
PlacidWay Medical Tourism
Phone: +1 888-296-6664
Email: [email protected]
Website: www.placidway.com